Update on intravenous iron choices

Derek S. Larson, Daniel W. Coyne

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Purpose of review Iron deficiency is a major factor in the prevalence and severity of anemia in patients with chronic kidney disease (CKD). We review the pathophysiology impairing normal intestinal iron absorption in CKD and compare the characteristics of newer intravenous (i.v.) iron agents to the longstanding i.v. iron products in the market. Recent findings The newer iron products, ferumoxytol, ferric carboxymaltose, and iron isomaltoside, more avidly bind iron, minimizing the release of labile iron during infusions, thus permitting large dose infusions. These irons also have more complex carbohydrate shells than their predecessors, which may also diminish reactions. Newer agents can be routinely administered at higher single doses, in as little as 15 min, with an acceptable safety profile. Summary Newer i.v. iron products permit the rapid, and sometimes complete, repletion of iron-deficient patients with a single dose. However, further studies examining the long-term risks and benefits of i.v. iron repletion are needed.

Original languageEnglish
Pages (from-to)186-191
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Issue number2
StatePublished - Mar 1 2014


  • Anaphylaxis
  • Erythropoiesis
  • Hepcidin

Fingerprint Dive into the research topics of 'Update on intravenous iron choices'. Together they form a unique fingerprint.

Cite this